And announces progress for Loramyc® commercialization in Italy
PARIS--(BUSINESS WIRE)-- Regulatory News:
BioAlliance Pharma SA (Paris:BIO), a company dedicated to specialty and orphan oncology products, today reported a consolidated turnover of €332,000 for the quarter of 2011 and announced progress for Loramyc® commercialization in Italy.
This turnover is nearly equally made of our partners’ international activities on Loramyc®/Oravig® (royalties and sales) and to the staggered upfront payments received from the licensing agreements.
Price and reimbursement discussions are being finalized between Therabel and the Italian Health Authorities, which should then be confirmed in Italian official journal. It will be a key step, allowing Therabel to prepare Loramyc® launch on this new territory, extending Loramyc® presence in Europe, already available in France and Germany.
Key milestones have been achieved during the last months fostering the Company’s growth strategy:
- The submission of European registration dossier for Sitavir®, antiviral drug based on the Lauriad™ mucoadhesive technology with a unique efficacy profile in the treatment of recurrent herpes labialis treatment.
- The green light from the French Agency for the phase III of Livatag®, leader of the “Orphan oncology products” portfolio, which should be initiated in the treatment of primary liver cancer in 2012.
- The grant of orphan status designation for clonidine Lauriad™ in Europe in the prevention of radiotherapy-induced oral mucositis in patients with head and neck cancer, allowing to optimize the development plan in terms of costs and timelines and reinforcing its protection (commercial exclusivity).
« These significant achievements demonstrate the ability and know-how of BioAlliance’s teams to develop a diversified and balanced portfolio, enhancing the unique profile of the Company in our area of activity”, declares Judith Greciet, CEO of BioAlliance Pharma. “With a level of cash reaching €28.2 million end of September, strongly reinforced after our capital increase last summer, we are able to pursue our R&D programs, notably our most advanced projects”.
About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products –– BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)
Sitavir® (Acyclovir Lauriad TM) (labialis herpes): Positive phase III final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results
Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) in primary) liver cancer: Authorization for Phase III clinical trial
Clonidine LauriadTM (mucositis): Phase II on going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Judith Greciet, CEO
Tel +33 1 45 58 76 00
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59
KEYWORDS: Europe France
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical